Edition:
United Kingdom

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

3.04EUR
4:35pm GMT
Change (% chg)

€-0.01 (-0.49%)
Prev Close
€3.05
Open
€3.08
Day's High
€3.08
Day's Low
€3.01
Volume
46,009
Avg. Vol
166,926
52-wk High
€3.79
52-wk Low
€2.40

Latest Key Developments (Source: Significant Developments)

Transgene Collaborates with BioInvent To Treat Solid Tumors
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - TRANSGENE SA ::BIOINVENT AND TRANSGENE COLLABORATE ON NEXT GENERATION ONCOLYTIC VIRUSES ENCODING AN ANTI-CTLA-4 ANTIBODY TO TREAT SOLID TUMORS.‍COLLABORATION'S RESEARCH AND DEVELOPMENT COSTS, AS WELL AS REVENUES AND ROYALTIES, WILL BE SHARED 50:50​.WILL CONTRIBUTE BOTH ITS OV DESIGN AND ENGINEERING EXPERTISE AS WELL AS ITS PROPRIETARY ENGINEERED VACCINIA VIRUS.  Full Article

Transgene successfully raises 14.4 million euros
Friday, 10 Nov 2017 

Nov 10 (Reuters) - TRANSGENE SA ::TRANSGENE SUCCESSFULLY RAISES € 14.4 MILLION FROM U.S. AND EUROPEAN INVESTORS.‍TRANSACTION WAS OVERSUBSCRIBED, AT EUR 2.55 PER SHARE​.‍NEW SHARES WILL HAVE A PAR VALUE OF ONE EURO EACH​.‍NEW SHARES CARRY DIVIDEND RIGHTS AS FROM THEIR ISSUE DATE​.‍NEW SHARES' ADMISSION TO TRADING EXPECTED TO OCCUR ON NOV 14, 2017 ON EURONEXT IN PARIS​.  Full Article

Transgene launches capital increase by accelerated book-build offering
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - TRANSGENE SA ::TRANSGENE LAUNCHES A CAPITAL INCREASE BY WAY OF AN ACCELERATED BOOK-BUILD OFFERING.‍CAPITAL INCREASE WITHOUT PREFERENTIAL SUBSCRIPTION RIGHTS THROUGH ISSUANCE OF UP TO 5,643,199 ORDINARY SHARES​.‍TO ISSUE OF UP TO 5,643,199 ORDINARY SHARES OF COMPANY, REPRESENTING APPROXIMATELY 10% OF EXISTING ISSUED SHARE CAPITAL​.‍GROSS PROCEEDS FROM TRANSACTION ARE EXPECTED TO BE APPROXIMATELY EUR 14 MILLION​.‍FUNDS RAISED WILL BE USED TO PURSUE CLINICAL AND PRECLINICAL DEVELOPMENT OF TRANSGENE'S INNOVATIVE IMMUNOTHERAPIES​.‍ADMISSION TO TRADING OF NEW SHARES EXPECTED TO OCCUR ON NOVEMBER 14, 2017 ON EURONEXT IN PARIS​.  Full Article

Transgene Q3 operating revenue drops to 1.4‍​ million euros
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - TRANSGENE SA ::Q3 OPERATING REVENUE EUR 1.4‍​ MILLION VERSUS EUR 1.5 MILLION YEAR AGO.CASH AND CASH EQUIVALENTS AT SEPT. 30 EUR 40.0‍​ MILLION VERSUS EUR 56.2 MILLION AT DEC. 31, 2016.CONFIRMS OUTLOOK OF CASH BURN ABOUT 30 MILLION EUROS‍​ IN FY 2017.  Full Article

Transgene announces collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate the combination of TG4001 with Avelumab
Tuesday, 11 Oct 2016 

Transgene : Transgene announces collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate the combination of TG4001 with Avelumab in HPV-positive head & neck cancer in a phase 1/2 study . Transgene- this is an exclusive agreement between parties to study combination of these two classes of investigational agents in HPV-positive HNSCC .Transgene- phase I trial is expected to begin in France, with first patient expected to be recruited in H1 2017.  Full Article

Transgene H1 net loss narrows to 12.2 million euros
Monday, 5 Sep 2016 

Transgene Sa : H1 operating loss from continuing operations 10.7 million euros ($11.93 million) versus 20.2 million euros year ago . H1 net loss 12.2 million euros versus 28.1 million euros year ago . H1 revenue 4.9 million euros versus 5.3 million euros year ago . Transgene confirms that it expects its cash burn to be around 35 million euros in 2016 .33.4 million euros in cash and cash equivalents as of June 30, 2016.  Full Article

Transgene hires two senior pharmaceutical industry executives
Thursday, 17 Mar 2016 

Transgene SA:Transgene hires two senior pharmaceutical industry executives to join leadership team.  Full Article

Transgene comments on FY 2016 guidance
Tuesday, 8 Mar 2016 

Transgene SA:Expects cash burn for 2016 to be around 35 million euros.From 2016, expects a reduction in overall operating costs of more than 10 million euros compared to full year 2015.  Full Article

French and Benelux stocks-Factors to watch on Jan 18

Jan 18 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.